ストックスクリーナーアプリを入手
9.63
0.10%
-0.010
前日終値:
$9.64
開ける：
$9.5
24時間の取引高:
7,342
Relative Volume:
0.82
時価総額：
$681.59M
収益：
$370.44M
当期純損益:
$12.19M
株価収益率:
55.89
EPS:
0.1723
ネットキャッシュフロー:
$50.74M
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
-8.72%
6か月 パフォーマンス:
-45.90%
1年 パフォーマンス:
-33.01%
1日の値動き範囲:
$9.50
$10.03
1週間の範囲:
$9.32
$10.03
52週間の値動き範囲:
$9.32
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
9.63 | 681.59M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-09 | 開始されました | Jefferies | Buy |
Pharming Group Nv Adr (PHAR) 最新ニュース
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusAnalyst Drop Coverage - careplusvn.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusEarnings Season Preview - dars.gov.et
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusBalance Sheet Strength - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusHagopian Line - careplusvn.com
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusDescending Triangle - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusOversold Bounce Ideas - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming (PHAR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Investor Response: Shares Move Lower 0.30% in the Current UpdateSlow Growth Warning - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayEarnings Preview - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayMargin Expansion Trends - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureTrading Ideas - careplusvn.com
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureInsider Selling Alerts - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Pharming (PHAR) Q2 2026 Earnings: 90% EPS Miss Overshadowed by Resilient Share PriceRevenue Warning Signal - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Pharming Group (PHAR) Advances 1.93% to $10.01, Approaches Key Resistance at $10.51IV Spike - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffCFO Commentary Report - careplusvn.com
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffSurprise Factor Analysis - dars.gov.et
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffEarnings Surprise Score - https://www.dars.gov.et/
Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure - investing.com
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
Pharming Group Nv Adr (PHAR) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
3.96%
大文字化:
|
ボリューム (24 時間):